- Home
- SRZN vs RCEL Comparison
SRZN vs RCEL Comparison
Compare SRZN & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRZN | RCEL |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.8M | 102.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SRZN | RCEL |
|---|---|---|
| Price | $19.67 | $3.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $38.50 | $8.67 |
| AVG Volume (30 Days) | 100.8K | ★ 197.9K |
| Earning Date | 11-07-2025 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $3,604,000.00 | ★ $72,401,000.00 |
| Revenue This Year | N/A | $13.12 |
| Revenue Next Year | N/A | $27.56 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 20.59 |
| 52 Week Low | $5.90 | $3.25 |
| 52 Week High | $24.94 | $14.16 |
Technical Indicators
Market Signals| Indicator | SRZN | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 48.30 | 41.28 |
| Support Level | $21.03 | $3.36 |
| Resistance Level | $23.42 | $3.61 |
| Average True Range (ATR) | 1.84 | 0.18 |
| MACD | -0.60 | 0.03 |
| Stochastic Oscillator | 28.45 | 34.78 |
Price Performance
Historical ComparisonAbout SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.